Skip to main content

Table 1 Baseline characteristics of patients with mild-moderate Alzheimer's disease who were treated with donepezil for 6 months, by ADAS-Cog response group

From: The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

 

All patients

ADAS-Cog

ADAS-Cog

ADAS-Cog

 

(n = 95)

improved

no change

worsened

  

(n = 19)

(n = 53)

(n = 23)

Baseline characteristics

    

   Females, n (%)

68 (72)

15 (79)

36 (68)

17 (74)

   Age, mean years (sd)

75.8 (7.7)

79.8 (8.2)

75.5 (6.3)

73.3 (8.9)

   Education, mean years (sd)

11.1 (3.2)

10.5 (3.2)

11.0 (3.2)

11.6 (3.2)

   Duration of illness, mean years (sd)

1.3 (1.5)

1.0 (1.0)

1.3 (1.7)

1.5 (1.6)

   CDR = mild, n (%)

73 (77)

14 (74)

44 (83)

15 (65)

Baseline outcomes

    

   CIBIS+, mean (sd)

3.7 (0.8)

3.7 (0.8)

3.6 (0.7)

3.9 (0.7)

   MMSE, mean (sd)

19.9 (5.3)

20.0 (4.7)

20.6 (5.3)

18.3 (5.4)

   ADAS-Cog, mean (sd)

24.6 (9.9)

26.4 (10.6)

23.2 (9.3)

26.3 (10.4)

   PSMS, mean (sd)

8.8 (2.5)

9.3 (2.1)

8.8 (2.7)

8.3 (2.2)

   IADL, mean (sd)

19.9 (5.4)

20.5 (4.6)

20.1 (5.4)

18.9 (6.1)

   CSD, mean (sd)

5.7 (5.4)

6.4 (5.5)

5.5 (5.1)

5.9 (6.2)

Treatment goals set at baseline

    

   PGAS-total, mean (sd)

8.6 (3.3)

8.2 (2.7)

8.7 (3.3)

8.6 (3.8)

   PGAS-cognition, mean (sd)1

1.2 (0.8)

1.1 (0.7)

1.2 (0.8)

1.2 (0.7)

   CGAS-total, mean (sd)

3.4 (1.3)

3.1 (0.8)

3.5 (1.4)

3.3 (1.2)

   CGAS-cognition, mean (sd)2

2.1 (1.8)

2.5 (2.3)

2.2 (1.7)

1.8 (1.4)

  1. 1 81/95 patients/caregivers set cognition goals: respectively 16/19, 45/53 and, 20/23
  2. 2 81/95 clinicians set cognition goals, respectively 17/19, 45/53 and 19/23